logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Statement of the American Society of Clinical Oncology : Genetic testing for cancer susceptibility. Commentaries.

    Article - En anglais

    As the leading organization of physicians who treat people with cancer, the American Society of Clinical Oncology (ASCO) recognizes that cancer specialists must be fully informed of the range of issues involved in genetic testing for cancer risk.

    The newly discovered and still developing ability to identify individuals at highest risk for cancer holds the promise of improved prevention and early detection of cancers.

    It also poses potential medical, psychological, and other personal risks that must be addressed in the context of informed consent for genetic testing.

    ASCO firmly believes that any physician who offers genetic testing should be aware of, and able to communicate, the benefits and limits of current testing procedures, and the range of prevention and treatment options available to patients and their families.

    For these reasons, ASCO endorses the following principles : ASCO affirms the role of clinical oncologists in documenting a family history of cancer in their patients, providing counseling regarding familial cancer risk and options for prevention and early detection, and recognizing those families for which genetic testing may serve as an aid in counseling..

    To the greatest extent possible, genetic testing for cancer susceptibility should be performed in the setting of long-term outcome studies.

    ASCO endorses the formulation and implementation of a national cooperative study/registry with appropriate confidentiality to define the clinical si...

    Mots-clés Pascal : Tumeur maligne, Homme, Facteur risque, Prévention, Prédisposition, Déterminisme génétique, Conseil génétique, Médecin, Pratique professionnelle, Consentement éclairé, Législation, Recommandation, Etats Unis, Amérique du Nord, Amérique, Personnel sanitaire

    Mots-clés Pascal anglais : Malignant tumor, Human, Risk factor, Prevention, Predisposition, Genetic inheritance, Genetic counseling, Physician, Professional practice, Informed consent, Legislation, Recommendation, United States, North America, America, Health staff

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0256466

    Code Inist : 002B04A. Création : 199608.